3SBio Inc - Asset Resilience Ratio
3SBio Inc (83B) has an Asset Resilience Ratio of 19.88% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 3SBio Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how 3SBio Inc's Asset Resilience Ratio has changed over time. See 83B book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down 3SBio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of 3SBio Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €4.74 Billion | 19.88% |
| Total Liquid Assets | €4.74 Billion | 19.88% |
Asset Resilience Insights
- Good Liquidity Position: 3SBio Inc maintains a healthy 19.88% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
3SBio Inc Industry Peers by Asset Resilience Ratio
Compare 3SBio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Merus BV
NASDAQ:MRUS |
Biotechnology | 29.69% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 30.29% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
|
Savara Inc
NASDAQ:SVRA |
Biotechnology | 76.71% |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871 |
Biotechnology | 9.59% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 3.87% |
Annual Asset Resilience Ratio for 3SBio Inc (2016–2024)
The table below shows the annual Asset Resilience Ratio data for 3SBio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.57% | €3.77 Billion ≈ $4.41 Billion |
€24.21 Billion ≈ $28.31 Billion |
+1.59pp |
| 2023-12-31 | 13.98% | €3.30 Billion ≈ $3.86 Billion |
€23.63 Billion ≈ $27.62 Billion |
-8.13pp |
| 2022-12-31 | 22.11% | €4.86 Billion ≈ $5.68 Billion |
€21.99 Billion ≈ $25.71 Billion |
+12.22pp |
| 2021-12-31 | 9.89% | €1.90 Billion ≈ $2.22 Billion |
€19.21 Billion ≈ $22.46 Billion |
+2.69pp |
| 2020-12-31 | 7.20% | €1.27 Billion ≈ $1.49 Billion |
€17.68 Billion ≈ $20.67 Billion |
+4.01pp |
| 2019-12-31 | 3.19% | €472.16 Million ≈ $552.01 Million |
€14.81 Billion ≈ $17.31 Billion |
+2.70pp |
| 2018-12-31 | 0.49% | €68.13 Million ≈ $79.65 Million |
€13.84 Billion ≈ $16.18 Billion |
-4.63pp |
| 2017-12-31 | 5.12% | €704.56 Million ≈ $823.71 Million |
€13.75 Billion ≈ $16.08 Billion |
+1.84pp |
| 2016-12-31 | 3.28% | €362.17 Million ≈ $423.42 Million |
€11.04 Billion ≈ $12.91 Billion |
-- |
About 3SBio Inc
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER… Read more